



Cardiovascular diseases such as attacks and strokes are the world's leading causes of death. During a some of the become starved of blood and die. These cells are rarely replaced due to the heart's limited regenerative ability, which means that patients have to live with the limitations of a damaged heart.

Steve Oh led a team of researchers from the A*STAR Bioprocessing Technology Institute in designing a prototype 'platform' that enables heart muscle cells, or cardiomyocytes, to be produced from human pluripotent . Oh believes that this platform could be scaled up to industrial production levels2.

"The key is to be able to produce these cells in bulk," says Oh. "Eventually we will be able to produce trillions of cells, but our current work involves developing the prototype process that is generating hundreds of millions of cells per batch."

Traditionally, tissue culture is grown on a flat plate, but Oh's team used 'microcarriers'—tiny polystyrene spheres that are electrically charged and coated with a protein—as the base for their culture (see image).

"Stem cells like to grow as clusters," says Oh. "These microcarriers enable them to do that while suspended in a spinner flask, which is better for bulk production," says Oh.

An automated video analysis technique can be used to observe newly grown heart cells as they regularly contract or beat. Credit: A*STAR Bioprocessing Technology Institute

Researchers typically agitate stem cell cultures to help the cells receive nutrients and prevent them from clumping. Oh's team conducted extensive research into the optimal levels of agitation required to increase the number of cells produced. They showed that too much agitation in the first few days of culture growth is detrimental3.

The team developed two effective protocols: one using stirring and another employing a rocking motion. "Both approaches have potential for industrial scale production," says Oh.


"Before the video analysis system, we had to depend on experienced eyes to identify beating microcarrier–cell aggregates," says Oh.

The next step for the group is to scale up production to more commercially useful levels. The process currently uses a 50 milliliter flask of microcarriers and stem , but, says Oh, "We need to take it to a one liter controlled bioreactor."

Explore further

Recipient of novel stem cell treatment 'well', doctor





Journal information: Stem Cell Research

Citation: A scalable platform for growing heart muscle cells may lead to repair of damaged heart cells (2015, January 21) retrieved 20 November 2019 from https://medicalxpress.com/news/2015-01-scalable-platform-heart-muscle-cells.html

Feedback to editors

User comments